Tissue Regenix Group

Tissue Regenix Group is a medical technology company focused on developing and commercializing innovative technologies in the field of tissue engineering and regenerative medicine. Founded in 2006, the company has its roots in research conducted at the University of Leeds. Tissue Regenix operates through several divisions, including BioSurgery, Orthopaedics & Dental, Cardiac, and GBM-V. The company is known for its dCELL technology, which decellularizes biological tissues to create new, accepting tissue that reduces rejection risks and promotes natural healing. Additionally, it offers BioRinse, a natural bone filler, and various other products such as DermaPure, SurgiPure XD, and OrthoPure XT, which are designed to support tissue repair and regeneration. Their diverse product line also includes bone matrices and grafts that enhance surgical outcomes in various medical applications. With operations primarily in the United States and internationally, Tissue Regenix aims to address complex clinical needs through its advanced regenerative product offerings.

Jonathan Glenn

Chairman

1 past transactions

CellRight

Acquisition in 2017
CellRight Technologies operates as a biotechnology company. The Company specializes in regenerative medicine and develops osteoinductive and wound care scaffolds to improve healing opportunities of defects created by trauma and disease. CellRight Technologies serves customers in the State of Texas. CellRight Technologies is the industry leader of osteoinductive matrices and is committed to providing clinicians and their patients with verified osteoinductive implants known to positively impact patient and fusion outcomes. In-vivo and in-vitro testing to verify osteoinductivity is performed post-sterilization by an independent testing laboratory using validated osteoinductivity test methods.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.